--- title: "Pharmaron rose over 8% in half a day, receiving a target price upgrade from Nomura" type: "News" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/281302865.md" description: "Pharmaron's stock price rose 8.61% today, closing at 20.44 yuan, with a trading volume of 9.5382 million shares. Nomura reported that Pharmaron's performance in the fourth quarter of last year met expectations, with revenue and profit increasing by 16% and 41%, respectively. It is expected that revenue will grow by 12% to 18% in 2026. Nomura raised the target price from 26.63 yuan to 27.33 yuan and maintained a \"Buy\" rating" datetime: "2026-04-01T04:39:29.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/281302865.md) - [en](https://longbridge.com/en/news/281302865.md) - [zh-HK](https://longbridge.com/zh-HK/news/281302865.md) --- > 支持的语言: [English](https://longbridge.com/en/news/281302865.md) | [繁體中文](https://longbridge.com/zh-HK/news/281302865.md) # Pharmaron rose over 8% in half a day, receiving a target price upgrade from Nomura Pharmaron (03759.HK) opened up 2.87% today, reaching a high of HKD 20.64. It closed at HKD 20.44 at noon, up 8.61%, with a trading volume of 9.5382 million shares, involving HKD 190 million. Nomura published a report stating that Pharmaron's performance in the fourth quarter of last year met expectations, with revenue and profit growing by 16% and 41% year-on-year, respectively. Management expects revenue to grow by 12% to 18% year-on-year by 2026, which, based on the midpoint, aligns with market expectations but is higher than Nomura's original estimate. This growth guidance has taken into account exchange rate impacts; otherwise, the actual growth would be 3 percentage points higher. The firm believes that Pharmaron's CMC business growth will accelerate, and it is confident that the company's efforts to strengthen this business have begun to yield results. Recent investments from Eli Lilly (LLY.US) and orders for oral GLP-1 production support this view. Nomura has raised its revenue and profit forecasts for 2026 by 4.2% and lowered them by 10.5%, respectively. Nomura maintains a "Buy" rating on Pharmaron and has raised its target price based on a discounted cash flow model from HKD 26.63 to HKD 27.33, assuming a weighted average cost of capital (WACC) of 10% and a terminal growth rate of 4% ### 相关股票 - [PHARMARON (03759.HK)](https://longbridge.com/zh-CN/quote/03759.HK.md) - [Guotai CSI Bio-medicine ETF (512290.CN)](https://longbridge.com/zh-CN/quote/512290.CN.md) - [Yinhua CSI Innovative Drugs Industry ETF (159992.CN)](https://longbridge.com/zh-CN/quote/159992.CN.md) - [ChinaAMC SSE STAR Biology and Medicine ETF (588130.CN)](https://longbridge.com/zh-CN/quote/588130.CN.md) - [ChinaAMC CSI Biotechnology Theme ETF (516500.CN)](https://longbridge.com/zh-CN/quote/516500.CN.md) - [China Merchants CSI Biotechnology Theme ETF (159849.CN)](https://longbridge.com/zh-CN/quote/159849.CN.md) - [Pharmaron (300759.CN)](https://longbridge.com/zh-CN/quote/300759.CN.md) - [ChinaAMC SSE Health Care ETF Initiating Fund (510660.CN)](https://longbridge.com/zh-CN/quote/510660.CN.md) - [E Fund CSI Biotechnology Theme ETF (159837.CN)](https://longbridge.com/zh-CN/quote/159837.CN.md) - [Minsheng Royal CSI Biotechnology Theme ETF (516930.CN)](https://longbridge.com/zh-CN/quote/516930.CN.md) - [E Fund CSI 300 Health Care ETF (512010.CN)](https://longbridge.com/zh-CN/quote/512010.CN.md) ## 相关资讯与研究 - [Annovis Bio Director Purchased Shares Worth Over $1.4M](https://longbridge.com/zh-CN/news/281662341.md) - [3SBio Nearly Doubles Revenue and Quadruples Profit in 2025, Keeps Dividend Steady](https://longbridge.com/zh-CN/news/281054154.md) - [RemeGen Receives Chinese Regulatory Nod for RC288 Clinical Trial](https://longbridge.com/zh-CN/news/281458440.md) - [Biocytogen and Sihuan partner to advance new therapeutics for weight loss](https://longbridge.com/zh-CN/news/281501537.md) - [Xinhua Pharma Becomes Marketing Authorization Holder of Dental Drug After Regulatory Nod](https://longbridge.com/zh-CN/news/281343251.md)